CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION: NDA 50479/S015

CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tenative Approval Letter				X
Approvable Letter			X	
Final Printed Labeling		X		
Medical Review(s)	X			
Chemistry Review(s)			X	
EA/FONSI			X	
Pharmacology Review(s)			X	
Statistical Review(s)			X	
Microbiology Review(s)			X	
Clinical Pharmacology Biopharmaceutics Review(s)			X	
Bioequivalence Review(s)			X	
Administrative Document(s)			X	
Correspondence			X	

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number: NDA 50479/S015

Trade Name: Cortisporin Otic Solution

Generic Name: (Neomycin and polymyxin B sulfate and hydrocortisone, USP)

Sponsor: King Pharmaceuticals, Inc.

Approval Date: August 26, 1999

INDICATION: Provides for changes in the Pediatric and Geriatric Use subsections of the PRECAUTIONS section of the package insert.

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number: NDA 50479/S015

APPROVAL LETTER

HFD-520/DEASTWICK

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 50-479/S-015

AUG 26 1999

King Pharmaceuticals, Inc.
Attention: Suzanne E. Smith
Manager, Regulatory Affairs
501 Fifth Street
Bristol, Tennessee

Dear Ms. Smith:

Please refer to your supplemental new drug application dated March 23, 1999, received March 24, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cortisporin (Neomycin and polymyxin B sulfate and hydrocortisone, USP) Otic Solution. We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

This supplemental new drug application provides for changes in the **Pediatric** and **Geriatric Use** subsections of the **PRECAUTIONS** section of the package insert.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed draft labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed draft labeling (text for the package insert, immediate container and carton labels) as indicated below.

Pediatric Use subsection:

> The safety and effectiveness of CORTISPORIN Otic Solution in otitis externa have been established in the pediatric age group 2 years to 16 years of age. There is inadequate data to establish safety and effectiveness in otitis externa for pediatric patients under 2 years of age.

Geriatric Use subsection:

> Clinical studies of CORTISPORIN Otic Solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 50-479/S-015." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Ms. Frances V. LeSane, Regulatory Health Project Manager, at (301) 827-2125.

Sincerely,

/S/

Gary K. Chikami, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 50479/S015

MEDICAL REVIEW(S)

HFD-520/19951U

JUL 30 1999

Clinical Review of Labeling Supplement
NDA 50-479/S-015

Date of Submission: March 23, 1999

Date CDER Received: March 24, 1999

Date Assigned to Reviewer: April 16, 1999

Date of Review Initiation: July 15, 1999

Date Review to Supervisor: July 27, 1999

Drug: Cortisporin Otic Solution. Each mL of solution contains 10,000 units polymyxin B sulfate, neomycin sulfate equivalent to 3.5 mg neomycin base (0.35%) and 10 mg hydrocortisone (1%).

Applicant: King Pharmaceuticals, Inc.
Bristol, TN 37620

Indications: For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics.

Packaging: 10 mL dropper bottles.

Reason for Supplement: Submission of a new "Pediatric Use" subsection as required by the December 13, 1994 Federal Register statement concerning pediatric labeling, and a new "Geriatric Use" section as required by the August 27, 1997 Federal Register statement concerning geriatric labeling.

Related NDA's: The cover letter for this supplement states that similar supplements have been submitted to the Office of Generic Drugs for the following applications:

> NDA 60-613: Cortisporin Otic Suspension. This product contains the same active ingredients in the same amount as NDA 50-479. The products differ in their excipients. Cortisporin Otic Solution is formulated with an acidic pH, while Cortisporin Otic Suspension is in a neutral vehicle.
>
> NDA 62-822: Pediotic Suspension. This product also contains the same active ingredients in the same amount as NDA 50-479. The products differ in their excipients.

Material Reviewed: The submitted supplement and the Federal Register statements of December 13, 1994 and August 27, 1997 have been consulted in the review of this application.

Review: The proposed "Pediatric Use" subsection for this product reads as follows:

The applicant has submitted a publication (Ofloxacin Otic Solution for Treatment of Otitis Externa in Children and Adults, *Arch Otolaryng Head Neck Surg.* 1997; 123:1193-1200) in support of this statement. These studies compared Cortisporin Otic Solution to ofloxacin otic solution (Floxin Otic), and were the basis for approval of NDA 20-799.

In the FDA medical reviewer's summary of evaluable patients in the NDA, 96% of the pediatric patients were found to be clinically cured, vs. 92% of the Cortisporin patients. Those rates were not found to be statistically different. A total of 158 subjects were found to be evaluable by the FDA reviewer (these numbers are lower than those seen in the referenced publication). There were very few patients in the Cortisporin group who were younger than 2 years of age, so the applicant's proposed age limitation is satisfactory. The publication provides adequate basis for the proposed "Pediatric Use" statement.

The proposed "Geriatric Use" subsection for this product reads as follows:

The draft guidance for content and format of geriatric labeling (December 11, 1998) provides for language of this type in general. There are no specific recommendations in the draft guidance, so the proposed paragraph is satisfactory.

Conclusions and Recommendations:

The proposed "Pediatric Use' and "Geriatric Use" subsections of the labeling are satisfactory. This supplement may be approved with draft labeling.

/S/

David Bostwick

/S/ 7-23-99

Alexander Rakowsky, M.D.

Concurrence Only: G. Chikami, Div. Dir.

/S/ 7/30/99

Original NDA
HFD-240
HFD-340
HFD-520
HFD-520/Bostwick
HFD-520/Rakowsky
HFD-520/PM/~~Dillon-Parker~~ LeSane